Case study: A phase 3 study of a candidate HIV vaccine

Joseph Millum, Ph.D.
Clinical Center Department of Bioethics/Fogarty International Center

5 November 2012
Disclaimer

- The views expressed are my own and do not represent the views of the NIH, DHHS, or any other US government agency
The vaccine

- You are part of a research network trying to develop an affordable HIV vaccine
- One candidate vaccine has been through phase 1 and 2 testing for safety and immunogenicity
- Phase 3 study necessary to show effectiveness in preventing HIV infection
A proposed study

- **Design**: Randomized placebo-controlled trial
- **Study population**: 1000 female sex workers from cities in sub-Saharan Africa
- **Exclusion**: HIV-positive
- **Standard of care**: HIV-testing, counseling about risk behaviors
- **Primary endpoint**: HIV status after 3 years
Questions

1. Is this an appropriate study population?
2. Is the preventive standard of care sufficient?
3. What should the researchers offer to
   - Potential participants who are screened out because HIV-positive?
   - Participants who sero-convert during the study?